Page 1 of 5SWGDRUG.org/monographs.htmLatest Revision: 11/4/2014
25I-NB4OMe The Drug Enforcement Administration's Special Testing and Research Laboratory
generated this monograph using structurally confirmed reference material.
1. GENERAL INFORMATION
IUPAC Name: 2-(4-iodo-2,5-dimethoxyphenyl)-N-(4-methoxybenzyl)ethanamine
CAS#: Not Available
Synonyms: N-(4-methoxybenzyl)-2-(4-iodo-2,5-dimethoxyphenyl)ethylamine4-Methoxy-25I-NBOMe
Source: DEA Reference Material Collection
Appearance: White powder
UVmax(nm): Not Determined
2. CHEMICAL AND PHYSICAL DATA
2.1 CHEMICAL DATA
Form Chemical Formula Molecular Weight Melting Point (oC)
Base C18H22INO3 427 Not Determined
HCl C18H22INO3 HCl 463 170.4
OCH3
I O
CH3
NH
OCH3
Page 2 of 5SWGDRUG.org/monographs.htmLatest Revision: 11/4/2014
25I-NB4OMeThe Drug Enforcement Administration's Special Testing and Research Laboratory
generated this monograph using structurally confirmed reference material.
3. QUALITATIVE DATA
3.1 NUCLEAR MAGNETIC RESONANCE
Sample Preparation: Dilute analyte to ~12 mg/mL inCDCl3 containing TMS for 0 ppm reference andmethenamine as quantitative internal standard.
Instrument: 400 MHz NMR spectrometerParameters: Spectral width: at least containing -3 ppm through 13 ppm
Pulse angle: 90o
Delay between pulses: 45 seconds1H NMR 25I-NB4OMe HCl Lot N17-P75C, CDCl3, 400MHz
7 6 5 4 3 2 1 0
0
1
2
3
4
5
6
7
8
9
10
46321212
TMS
*
CDCl3
Methenamine
7.50 7.45
2
7.1757.150
1
3.10 3.00
4
3.9 3.8 3.7
632
6.85 6.80 6.75
12
Page 3 of 5SWGDRUG.org/monographs.htmLatest Revision: 11/4/2014
25I-NB4OMeThe Drug Enforcement Administration's Special Testing and Research Laboratory
generated this monograph using structurally confirmed reference material.
3.2 GAS CHROMATOGRAPHY/MASS SPECTROMETRY
Sample Preparation: Dilute analyte ~6 mg/mL in CHCl3.
Instrument: Agilent gas chromatograph operated in split mode with MS detectorColumn: DB-1 MS (or equivalent); 30m x 0.25 mm x 0.25 µmCarrier Gas: Helium at 1 mL/minTemperatures: Injector: 280oC
MSD transfer line: 280oCMS Source: 230oCMS Quad: 150oCOven program:
1) 100oC initial temperature for 1.0 min2) Ramp to 300oC at 12 oC/min3) Hold final temperature for 9.0 min
Injection Parameters: Split Ratio = 20:1, 1 µL injectedMS Parameters: Mass scan range: 30-550 amu
Threshold: 100Tune file: stune.uAcquisition mode: scan
Retention Time: 16.739 minEI Mass Spectrum 25I-NB4OMe HCl, Lot N17-P75C
m/z40035030025020015010050
[x 1
06 ]In
tens
ity
1
2
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
291
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
164
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
919191 9191919191 9191919191 9191919191 91919191777777 7777777777 7777777777 7777777777 77777777656565 6565656565 6565656565 6565656565 65656565515151 5151515151 5151515151 5151515151 51515151EI+
m/z40035030025020015010050
[x 1
04 ]In
tens
ity
1 427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
427
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
394
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
320
32029
129
129
129
129
129
129
129
129
129
129
129
129
129
129
129
129
129
129
129
129
129
1232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
232
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219
219191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
191
19116
416
416
416
416
416
416
416
416
416
416
416
416
416
416
416
416
416
416
416
416
416
4
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
150
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
135
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
121
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
105
919191 9191919191 9191919191 9191919191 91919191777777 7777777777 7777777777 7777777777 77777777656565 6565656565 6565656565 6565656565 65656565515151 5151515151 5151515151 5151515151 51515151
EI+
1700 1600 1500 1400 1300 1200 1100 1000 900 800 700 Wavenumber (cm-1) Latest Revision: 11/4/2014 SWGDRUG.org/monographs.htm Page 4 of 5
25I-NB4OMeThe Drug Enforcement Administration's Special Testing and Research Laboratory
generated this monograph using structurally confirmed reference material.
3.3 INFRARED SPECTROSCOPY (FTIR)
Instrument: FTIR with diamond ATR attachment (3 bounce)Scan Parameters: Number of scans: 32
Number of background scans: 32Resolution: 4 cm-1
Sample gain: 8Aperture: 150
FTIR ATR (Diamond, 3 Bounce) 25I-NB4OMe HCl (Lot N17-P75C)
Wavenumber (cm-1)3500 3000 2500 2000 1500
%Tr
ansm
ittan
ce
55
60
65
70
75
80
29412941294129412941294129412941294129412941294129412941294129412941294129412941294129412908290829082908290829082908290829082908290829082908290829082908290829082908290829082908
2837283728372837283728372837283728372837283728372837283728372837283728372837283728372837 2794
279427942794279427942794279427942794279427942794279427942794279427942794279427942794
2754275427542754275427542754275427542754275427542754275427542754275427542754275427542754
2710271027102710271027102710271027102710271027102710271027102710271027102710271027102710
2648264826482648264826482648264826482648264826482648264826482648264826482648264826482648 1614
161416141614161416141614161416141614161416141614161416141614161416141614161416141614
1518151815181518151815181518151815181518151815181518151815181518151815181518151815181518
1489148914891489148914891489148914891489148914891489148914891489148914891489148914891489
1439143914391439143914391439143914391439143914391439143914391439143914391439143914391439
1381138113811381138113811381138113811381138113811381138113811381138113811381138113811381
1306130613061306130613061306130613061306130613061306130613061306130613061306130613061306
1254125412541254125412541254125412541254125412541254125412541254125412541254125412541254
1209120912091209120912091209120912091209120912091209120912091209120912091209120912091209
1178117811781178117811781178117811781178117811781178117811781178117811781178117811781178
1113111311131113111311131113111311131113111311131113111311131113111311131113111311131113
1032103210321032103210321032103210321032103210321032103210321032103210321032103210321032
984984984984984984984984984984984984984984984984984984984984984984
945945945945945945945945945945945945945945945945945945945945945945
850850850850850850850850850850850850850850850850850850850850850850
818818818818818818818818818818818818818818818818818818818818818818
791791791791791791791791791791791791791791791791791791791791791791 733
733733733733733733733733733733733733733733733733733733733733733
708708708708708708708708708708708708708708708708708708708708708708
661661661661661661661661661661661661661661661661661661661661661661
563563563563563563563563563563563563563563563563563563563563563563521521521521521521521521521521521521521521521521521521521521521521
478478478478478478478478478478478478478478478478478478478478478478
%Tr
ansm
ittan
ce
55
60
65
70
75
80
1614161416141614161416141614161416141614161416141614161416141614161416141614161416141614
1583158315831583158315831583158315831583158315831583158315831583158315831583158315831583
1518151815181518151815181518151815181518151815181518151815181518151815181518151815181518
1489148914891489148914891489148914891489148914891489148914891489148914891489148914891489
1439143914391439143914391439143914391439143914391439143914391439143914391439143914391439
1381138113811381138113811381138113811381138113811381138113811381138113811381138113811381
1354135413541354135413541354135413541354135413541354135413541354135413541354135413541354 1306
130613061306130613061306130613061306130613061306130613061306130613061306130613061306
1254125412541254125412541254125412541254125412541254125412541254125412541254125412541254
1209120912091209120912091209120912091209120912091209120912091209120912091209120912091209
1178117811781178117811781178117811781178117811781178117811781178117811781178117811781178
1113111311131113111311131113111311131113111311131113111311131113111311131113111311131113
1032103210321032103210321032103210321032103210321032103210321032103210321032103210321032
984984984984984984984984984984984984984984984984984984984984984984
945945945945945945945945945945945945945945945945945945945945945945
850850850850850850850850850850850850850850850850850850850850850850
818818818818818818818818818818818818818818818818818818818818818818
791791791791791791791791791791791791791791791791791791791791791791 733
733733733733733733733733733733733733733733733733733733733733733
708708708708708708708708708708708708708708708708708708708708708708
661661661661661661661661661661661661661661661661661661661661661661
563563563563563563563563563563563563563563563563563563563563563563521521521521521521521521521521521521521521521521521521521521521521
478478478478478478478478478478478478478478478478478478478478478478 411
411411411411411411411411411411411411411411411411411411411411411
Page 5 of 5SWGDRUG.org/monographs.htmLatest Revision: 11/4/2014
25I-NB4OMeThe Drug Enforcement Administration's Special Testing and Research Laboratory
generated this monograph using structurally confirmed reference material.
4. ADDITIONAL RESOURCES
Casale, J. and Hays, P. Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOME) Derivatives and Differentiation from their 3- and 4- methoxybenzyl analogs. Part 1. Microgram Journal, 2012; 9(2):84-109.